Verzenio is an anti-cancer drug owned by Eli Lilly And Co. The active ingredient in Verzenio is abemaciclib. Market authorization for Verzenio was granted on 28 September, 2017. The drug comes in tablet form and is administered orally.
The generic version of Verzenio is expected to be available after 15 December, 2029. This is the projected date upon the expiry of the last patent, US7855211, titled 'Protein kinase inhibitors'.
Verzenio is used extensively in the treatment of various stages of breast cancer. Its active ingredient, abemaciclib, works effectively in different combinations to treat postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. The drug is also used as monotherapy for advanced breast cancer patients with disease progression following endocrine therapy and prior chemotherapy.
Verzenio is protected by a patent that expires on 15 December, 2029, which indicates a possible timeline for Verzenio generic release. The patent, US7855211, is titled 'Protein kinase inhibitors'. Below are the details of the patent: